ApoB siRNA-induced liver steatosis is resistant to clearance by the loss of fatty acid transport protein 5 (Fatp5)

Lipids

Volumn 46, Issue 11, 2011, Pages 991-1003

  Ason, Brandon ^a   Castro Perez, Jose ^a,b   Tep, Samnang ^a   Stefanni, Alice ^a   Tadin Strapps, Marija ^a   Roddy, Thomas ^a   Hankemeier, Thomas ^b   Hubbard, Brian ^a   Sachs, Alan B ^a   Michael Flanagan, W ^a   Kuklin, Nelly A ^a   Mitnaul, Lyndon J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

APOB; FATP5; Liver steatosis; siRNA; siRNA combinations; Slc27a5

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BILE ACID; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLIC ACID; FATTY ACID TRANSPORTER; FATTY ACID TRANSPORTER 5; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LONG CHAIN FATTY ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TAUROCHOLIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY ACID SYNTHESIS; FATTY LIVER; FEMALE; GENE SILENCING; HEMIZYGOSITY; HISTOPATHOLOGY; LIPID COMPOSITION; LOW FAT DIET; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; APOLIPOPROTEINS B; BILE ACIDS AND SALTS; CHOLESTEROL; CHOLESTEROL, HDL; FATTY ACID TRANSPORT PROTEINS; FATTY LIVER; FEMALE; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; LIPID METABOLISM; LIVER; MICE; MICE, INBRED C57BL; RNA, SMALL INTERFERING; TRIGLYCERIDES;

MUS;

EID: 83555166075     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-011-3596-3     Document Type: Article

References (41)

1. D Steinberg 2004 Thematic review series: the pathogenesis of atherosclerosis-an interpretive history of the cholesterol controversy: part I J Lipid Res 45 1583 1593 10.1194/jlr.R400003-JLR200 15102877 10.1194/jlr.R400003- JLR200 1:CAS:528:DC%2BD2cXnvVWht7s%3D (Pubitemid 39296197)
2. D Steinberg 2005 Thematic review series: the pathogenesis of atherosclerosis-an interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans J Lipid Res 46 179 190 10.1194/jlr.R400012-JLR200 15547293 10.1194/jlr.R400012- JLR200 1:CAS:528:DC%2BD2MXhvFGktb0%3D (Pubitemid 40271080)
3. D Steinberg 2005 Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia J Lipid Res 46 2037 2051 15995167 10.1194/jlr.R500010-JLR200 1:CAS:528:DC%2BD2MXhtVygsr%2FP (Pubitemid 41377456)
4. D Steinberg 2006 Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy J Lipid Res 47 1339 1351 10.1194/jlr.R600009-JLR200 16585781 10.1194/jlr.R600009-JLR200 1:CAS:528:DC%2BD28XntVChtLo%3D (Pubitemid 44079887)
5. RA Davis TY Hui 2001 2000 George Lyman Duff Memorial Lecture: atherosclerosis is a liver disease of the heart Arterioscler Thromb Vasc Biol 21 887 898 11397693 10.1161/01.ATV.21.6.887 1:CAS:528:DC%2BD3MXksVaks7s%3D (Pubitemid 34168642)
6. K Skalen M Gustafsson EK Rydberg LM Hulten O Wiklund TL Innerarity J Boren 2002 Subendothelial retention of atherogenic lipoproteins in early atherosclerosis Nature 417 750 754 12066187 10.1038/nature00804 1:CAS:528:DC%2BD38XksVGjuro%3D (Pubitemid 34640629)
7. J Hulthe B Fagerberg 2002 Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study) Arterioscler Thromb Vasc Biol 22 1162 1167 12117732 10.1161/01.ATV.0000021150. 63480.CD 1:CAS:528:DC%2BD38XlsFSgsrk%3D (Pubitemid 34764868)
8. NO Davidson GS Shelness 2000 Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation Annu Rev Nutr 20 169 193 10940331 10.1146/annurev.nutr.20.1.169 1:CAS:528:DC%2BD3cXmsVKmu7s%3D
9. D Gaffney L Forster MJ Caslake D Bedford JP Stewart G Stewart G Wieringa M Dominiczak JP Miller CJ Packard 2002 Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia Atherosclerosis 162 33 43 11947895 10.1016/S0021-9150(01) 00679-7 1:CAS:528:DC%2BD38Xis1eisbs%3D (Pubitemid 34327339)
10. MJ Veerkamp J de Graaf SJ Bredie JC Hendriks PN Demacker AF Stalenhoef 2002 Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study Arterioscler Thromb Vasc Biol 22 274 282 11834528 10.1161/hq0202.104059 1:CAS:528: DC%2BD38Xhtlyjs74%3D (Pubitemid 34127039)
11. A Tybjaerg-Hansen R Steffensen H Meinertz P Schnohr BG Nordestgaard 1998 Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease N Engl J Med 338 1577 1584 9603795 10.1056/NEJM199805283382203 1:STN:280:DyaK1c3lt1Cltg%3D%3D (Pubitemid 28243987)
12. J Boren I Lee W Zhu K Arnold S Taylor TL Innerarity 1998 Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100 J Clin Invest 101 1084 1093 9486979 10.1172/JCI1847 1:CAS:528:DyaK1cXhs1yqsLk%3D (Pubitemid 28125287)
13. T Innerarity R Mahley K Weisgraber T Bersot R Krauss G Vega S Grundy W Friedl J Davignon B [tmp] Mc Carthy 1990 Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia J Lipid Res 31 1337 1349 2280177 1:CAS:528:DyaK3cXlvVyqtrk%3D (Pubitemid 20261898)
14. RM Crooke MJ Graham KM Lemonidis CP Whipple S Koo RJ Perera 2005 An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis J Lipid Res 46 872 884 15716585 10.1194/jlr.M400492-JLR200 1:CAS:528:DC%2BD2MXktFaqtb4%3D
15. DB Rozema DL Lewis DH Wakefield SC Wong JJ Klein PL Roesch SL Bertin TW Reppen Q Chu AV Blokhin, et al. 2007 Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes Proc Natl Acad Sci USA 104 12982 12987 10.1073/pnas.0703778104 17652171 10.1073/pnas.0703778104 1:CAS:528: DC%2BD2sXpt1KrtLg%3D (Pubitemid 351737577)
16. TS Zimmermann AC Lee A Akinc B Bramlage D Bumcrot MN Fedoruk J Harborth JA Heyes LB Jeffs M John, et al. 2006 RNAi-mediated gene silencing in non-human primates Nature 441 111 114 16565705 10.1038/nature04688 1:CAS:528: DC%2BD28XktVGlt7w%3D
17. J Soutschek A Akinc B Bramlage K Charisse R Constien M Donoghue S Elbashir A Geick P Hadwiger J Harborth, et al. 2004 Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs Nature 432 173 178 15538359 10.1038/nature03121 1:CAS:528:DC%2BD2cXpsF2gt7k%3D (Pubitemid 39545841)
18. E Merki MJ Graham AE Mullick ER Miller RM Crooke RE Pitas JL Witztum S Tsimikas 2008 Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice Circulation 118 743 753 18663084 10.1161/CIRCULATIONAHA.108.786822 1:CAS:528:DC%2BD1cXpsVChsrk%3D
19. CE Chandler DE Wilder JL Pettini YE Savoy SF Petras G Chang J Vincent HJ Harwood Jr 2003 CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans J Lipid Res 44 1887 1901 12837854 10.1194/jlr.M300094-JLR200 1:CAS:528:DC%2BD3sXos1GiurY%3D (Pubitemid 37356661)
20. Visser ME, Akdim F, Tribble DL, Nederveen AJ, Kwoh TJ, Kastelein JJ, Trip MD, Stroes ES Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 51:1057-1062
21. Akdim F, Visser ME, Tribble DL, Baker BF, Stroes ES, Yu R, Flaim JD, Su J, Stein EA, Kastelein JJ Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 105:1413-1419
22. F Akdim ES Stroes EJ Sijbrands DL Tribble MD Trip JW Jukema JD Flaim J Su R Yu BF Baker, et al. 2010 Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy J Am Coll Cardiol 55 1611 1618 20378080 10.1016/j.jacc.2009.11. 069 1:CAS:528:DC%2BC3cXmtlGrtr4%3D
23. FJ Raal RD Santos DJ Blom AD Marais MJ Charng WC Cromwell RH Lachmann D Gaudet JL Tan S Chasan-Taber, et al. 2010 Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 998 1006 20227758 10.1016/S0140-6736(10) 60284-X 1:CAS:528:DC%2BC3cXjs1ait74%3D
24. JJ Kastelein MK Wedel BF Baker J Su JD Bradley RZ Yu E Chuang MJ Graham RM Crooke 2006 Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B Circulation 114 1729 1735 17030687 10.1161/CIRCULATIONAHA.105. 606442 1:CAS:528:DC%2BD28XhtVKrt7vM (Pubitemid 44607121)
25. X Lin G Schonfeld P Yue Z Chen 2002 Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B38.9 mutation Arterioscler Thromb Vasc Biol 22 476 482 11884293 10.1161/hq0302.105271 (Pubitemid 34218757)
26. B Hubbard H Doege S Punreddy H Wu X Huang VK Kaushik RL Mozell JJ Byrnes A Stricker-Krongrad CJ Chou, et al. 2006 Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity Gastroenterology 130 1259 1269 16618417 10.1053/j.gastro.2006.02.012 1:CAS:528:DC%2BD28XksFWmu7g%3D
27. H Doege D Grimm A Falcon B Tsang TA Storm H Xu AM Ortegon M Kazantzis MA Kay A Stahl 2008 Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia J Biol Chem 283 22186 22192 18524776 10.1074/jbc.M803510200 1:CAS:528:DC%2BD1cXpt1arur4%3D
28. A Mencarelli B Renga E Distrutti S Fiorucci 2009 Antiatherosclerotic effect of farnesoid X receptor Am J Physiol Heart Circ Physiol 296 H272 H281 19028791 10.1152/ajpheart.01075.2008 1:CAS:528:DC%2BD1MXitVejsrs%3D
29. Tadin-Strapps M, Peterson LB, Cumiskey AM, Rosa RL, Mendoza VH, Castro-Perez J, Puig O, Zhang L, Strapps WR, Yendluri S et al. (2011) siRNA induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J Lipid Res 52:1084-1097
30. DV Morrissey JA Lockridge L Shaw K Blanchard K Jensen W Breen K Hartsough L Machemer S Radka V Jadhav, et al. 2005 Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs Nat Biotechnol 23 1002 1007 16041363 10.1038/nbt1122 1:CAS:528:DC%2BD2MXntVSrtrc%3D (Pubitemid 41114035)
31. HD Lieu SK Withycombe Q Walker JX Rong RL Walzem JS Wong RL Hamilton EA Fisher SG Young 2003 Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion Circulation 107 1315 1321 12628954 10.1161/01.CIR. 0000054781.50889.0C (Pubitemid 36314417)
32. H Doege RA Baillie AM Ortegon B Tsang Q Wu S Punreddy D Hirsch N Watson RE Gimeno A Stahl 2006 Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis Gastroenterology 130 1245 1258 16618416 10.1053/j.gastro.2006.02.006 1:CAS:528:DC%2BD28XksFWmu7s%3D
33. A Falcon H Doege A Fluitt B Tsang N Watson MA Kay A Stahl 2010 FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase Am J Physiol Endocrinol Metab 299 E384 E393 20530735 10.1152/ajpendo.00226.2010 1:CAS:528:DC%2BC3cXht1Wgu7nM
34. J Majercak WJ Ray A Espeseth A Simon XP Shi C Wolffe K Getty S Marine E Stec M Ferrer, et al. 2006 LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease Proc Natl Acad Sci USA 103 17967 17972 17098871 10.1073/pnas.0605461103 1:CAS:528:DC%2BD28Xht1Kmsr7E (Pubitemid 44852269)
35. F Wincott A DiRenzo C Shaffer S Grimm D Tracz C Workman D Sweedler C Gonzalez S Scaringe N Usman 1995 Synthesis, deprotection, analysis and purification of RNA and ribozymes Nucleic Acids Res 23 2677 2684 7544462 10.1093/nar/23.14.2677 1:CAS:528:DyaK2MXns1aksbo%3D
36. MT Abrams ML Koser J Seitzer SC Williams MA DiPietro W Wang AW Shaw X Mao V Jadhav JP Davide, et al. 2010 Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment Mol Ther 18 171 180 19738601 10.1038/mt.2009.208 1:CAS:528:DC%2BD1MXhtV2qt7nE
37. B Ason S Tep HR Davis Jr Y Xu G Tetzloff B Galinski F Soriano N Dubinina L Zhu A Stefanni, et al. 2011 Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9 J Lipid Res 52 679 687 21262787 10.1194/jlr.M013664 1:CAS:528:DC%2BC3MXktVOlt70%3D
38. KJ Livak TD Schmittgen 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method Methods 25 402 408 11846609 10.1006/meth.2001.1262 1:CAS:528:DC%2BD38XhtFelt7s%3D (Pubitemid 34164012)
39. EG Bligh WJ Dyer 1959 A rapid method of total lipid extraction and purification Can J Biochem Physiol 37 911 917 13671378 10.1139/o59-099 1:CAS:528:DyaG1MXhtVSgt70%3D
40. 2O labeling to quantify static and dynamic changes in cholesterol and cholesterol esters by high resolution LC/MS J Lipid Res 52 159 169 20884843 10.1194/jlr.D009787 1:CAS:528:DC%2BC3cXhs1arsbjK
41. E Fahy S Subramaniam RC Murphy M Nishijima CR Raetz T Shimizu F Spener G van Meer MJ Wakelam EA Dennis 2009 Update of the LIPID MAPS comprehensive classification system for lipids J Lipid Res 50 Suppl S9 S14 19098281 10.1194/jlr.R800095-JLR200